Volume 3, Number 2, Supplement 1 (March/April 2005)

Annual Review of Cytokines in Cancer Management

Summaries of selected studies of darbepoetin alfa, pegfilgrastim, pailifermin, and other cytokines presented at six major meetings held in 2004: 40th Annual Meeting of the American Society of Clinical Oncology • 46th Annual Meeting of the American Society of Hematology • 27th Annual San Antonio Breast Cancer Symposium • 29th Annual Congress of the Oncology Nursing Society • 39th Midyear Clinical Meeting of the American Society of Health-System Pharmacists • 2004 Annual Meeting of the American College of Clinical Pharmacy

Anemia

2

  

Darbepoetin Alfa in Anemia Management: A Vital Role in Cancer Care
Ralph Boccia, MD, Guest Editor

Center for Cancer and Blood Disorders, Bethesda, Maryland

full text 82 kb

6

  

Using Guidelines to Manage Anemia in Gynecologic Oncology Patients
Lisa Tangeman

full text 55 kb

8

  

Principles for the Successful Management of Chemotherapy-Induced Anemia When Implementing Clinical Pathways Into Standardized Practice
J. Ashley, Barry Fortner, S. Kirkland, Karen Miles, and Kelley Moore

full text 47 kb

10

  

CERA (Continuous Erythropoiesis Receptor Activator): Dose-Response, Pharmacokinetics, and Tolerability in Phase I Multiple Ascending Dose Studies
F.C. Dougherty, Bruno Reigner, Paul Jordan, and Anne Pannier

full text 51 kb

12

  

A Controlled, Randomized, Open-Label Study to Evaluate the Effects of Every-2-Week Darbepoetin Alfa for Anemia of Cancer
Veena Charu, Chandra Belani, Ahmad Gill, Mukesh Bhatt, Ali Ben-Jacob, Dianne Tomita, and Danica Katz

full text 56 kb

14

  

Improvements in Fatigue Are Associated With Early Treatment With Darbepoetin Alfa Every 3 Weeks in Anemic Patients Receiving Chemotherapy
Veena Charu, Bruce Saidman, Ali Ben-Jacob, Glen R. Justice, Ajit S. Maniam, Timothy Rearden, Dianne Tomita, and Greg Rossi

full text 59 kb

16

  

Correction/Maintenance Dosing (Front Loading) of Darbepoetin Alfa: Final Results from a Randomized Phase III Active-Controlled Trial
Dusan Kotasek, Jean Luc Canon, Jesus San Miguel, Michael Hedenus, Lisa Hendricks, Greg Rossi, and Kerry Taylor

full text 80 kb

18

  

Darbepoetin Alfa Radiosensitizes Tumors Independent of Anemia or the Correction of Anemia
Shoucheng Ning, Angus Sinclair, Cynthia Hartley, and Susan Knox

full text 54 kb

20

  

Increasing Hemoglobin Levels With Epoetin Alfa in Anemic Hematologic Cancer Patients Receiving Chemotherapy Correlates Significantly With Improved Quality of Life
Jean-Luc Harousseau, Pierre Fumoleau, Winand Lange, and Manfred Welslau

full text 56 kb

22

  

Expansion of Bone Marrow Progenitors and Mobilization of Multilineage Progenitor Cells Associated With Once-per-Cycle Administration of the Long-Acting Growth Factors Pegfilgrastim and Darbepoetin Alfa With Chemotherapy
Saroj Vadhan-Raj, Carlos E. Bueso-Ramos, G. Hangoc, K. Christopherson, M. Collard, and H.E. Broxmeyer

full text 51 kb

24

  

Efficacy of Darbepoetin Alfa in the Treatment of Chemotherapy-Induced Anemia in Non-Hodgkin’s Lymphoma
Stephanie A. Gregory, Douglas W. Blayney, Saroj Vadhan-Raj, Dianne K. Tomita, Greg Rossi, and Barry Mirtsching

full text 53 kb

26

  

Three-Times-Weekly Administration of Darbepoetin Alfa Appears to Be as Effective as 100 µg Once a Week in Chemotherapy-Induced Anemia: Results of a Clinical Trial Simulation
Balaji Agoram, Greg Rossi, and Anne C. Heatherington

full text 53 kb

28

  

Darbepoetin Alfa Maintains Hemoglobin Levels in Patients With Myelodysplastic Syndrome: Results of a Retrospective Cohort Study After Therapeutic Substitution From Epoetin Alfa
Jeffrey F. Patton, Yong Mun, and Joel F. Wallace

full text 51 kb

30

  

Comparable Efficacy and Safety of Darbepoetin Alfa 200 µg Every 2 Weeks and Epoetin Alfa 40,000 U Weekly in Patients With Breast Cancer: Results of a Randomized Comparison
Lee Schwartzberg, Lorrin Yee, Veena Charu, Dianne Tomita, Greg Rossi, and Frank Senecal

full text 52 kb

32

  

The Impact of Anemia and Neutropenia Treatment Visits on Breast Cancer Patients and Their Caregivers
Barry V. Fortner, Kurt T. Tauer, Ling Zhu, and Lee S. Schwartzberg

full text 48 kb

34

  

Assessing Symptom Burden in Breast Cancer Patients Treated With Darbepoetin Alfa 200 µg Every Two Weeks Using the M. D. Anderson Symptom Inventory
Charles Cleeland, Greg Rossi, and Janice Gabrilove

full text 80 kb

36

  

Dose-Dense Chemotherapy Supported by Pegfilgrastim and an Erythropoietic Agent in Operable Breast Cancer
Lee Schwartzberg, Kurt Tauer, Barry Fortner, Gina Johnson, and Qian Mao

full text 49 kb

Neutropenia

39

  

Advances in the Use of Colony-Stimulating Factors for Chemotherapy-Induced Neutropenia
David C. Dale, MD, Guest Editor

Department of Medicine, University of Washington School of Medicine, and Attending Physician, University of Washington Medical Center, Seattle, Washington

full text 72 kb

42

  

A Multicenter, Double-Blind, Randomized, Phase II Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukemia
Alberto Bosi, Jeffrey Szer, Jeannine Kassis, Jorge Sierra, Claire Desborough, and Karen Buchanan

full text 57 kb

44

  

A Phase II Study of Pegfilgrastim to Support ACE 14 Chemotherapy for the Treatment of Subjects With Small Cell Lung Cancer
R. Pirker, E. Ulsperger, K. Aigner, and J. Messner

full text 48 kb

46

  

Pegfilgrastim Supports Delivery of CHOP-R Chemotherapy Administered Every 14 Days: A Randomized Phase II Study
Andres Lopez, Alberto Fernandez de Sevilla, Sylvie Castaigne, Richard Greil, Jorge Sierra, Jordi Sanchez, Valerie Easton, and Pamela Bacon

full text 78 kb

48

  

Pegfilgrastim Supports Delivery of BEACOPP Chemotherapy Administered Every 14 Days
Andreas Engert, Hartmut Doehner, Anthony D. Ho, Norbert Schmitz, Henning Bredenfeld, Dieter Hoelzer, Beate Klimm, Axel Münz, Valerie Easton, Pamela Bacon, and Volker Diehl

full text 54 kb

50

  

Use of the Long-Acting Hematopoietic Growth Factors Pegfilgrastim and Darbepoetin Alfa in Support of Dose-Dense Adjuvant Chemotherapy
Harold J. Burstein, Leroy M. Parker, J. Doherty, Ann H. Partridge, Lidia Schapira, P.D. Ryan, J. Younger, Lyndsay N. Harris, B. Moy, C.A. Bunnell, S. Come, S. Schumer, M. Haldoupis, R. Gelman, and Eric P. Winer

full text 55 kb

52

  

First-Cycle Risk of Severe and Febrile Neutropenia in Cancer Patients Receiving Systemic Chemotherapy: Results From a Prospective Nationwide Study
Jeffrey Crawford, Debra Wolff, Eva Culakova, Marek S. Poniewierski, Caleb Selby, David Dale, and Gary H. Lyman for the ANC Study Group

full text 51 kb

54

  

Economic Analysis of Prophylactic Pegfilgrastim in Cancer Patients Receiving Chemotherapy
Adi Eldar-Lissai, Leon Cosler, and Gary H. Lyman

full text 51 kb

56

  

Risk of Neutropenic Complications Based on a Prospective Nationwide Registry of Cancer Patients Initiating Systemic Chemotherapy
Debra A. Wolff, Jeffrey Crawford, David C. Dale, Merek S. Poniewierski, and Gary H. Lyman for the ANC Study Group

full text 52 kb

58

  

Pegfilgrastim Nearly Abrogates Occurrence of Neutropenic Events Early in the Course of Chemotherapy: Results of a Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Patients With Breast Cancer Receiving Docetaxel
C. Vogel, M. Rader, S. Tyulandin, B. Wiens, T. Neumann, and R. Carroll

full text 55 kb

60

  

Average Relative Dose Intensity Correlates With Survival in Diffuse Large B-Cell Lymphoma Patients Treated by CHOP: A National Retrospective Study (1995–2000)
Andre Bosly, Dominique Bron, Achiel Van Hoof, Robbrecht De Bock, Zwi Berneman, Augustin Ferrant, and Gregor Verhoef

full text 55 kb

62

  

Development of a Neutropenia Risk-Assessment Tool
Rebecca B. Donohue and Glen Carbo

full text 51 kb

64

  

Phase II Study of a Single Pegfilgrastim Injection as an Adjunct to Chemotherapy to Mobilize Stem Cells Into Peripheral Blood of Pretreated Lymphoma Patients
Roberto M. Lemoli, Alessandro Isidori, Monica Tani, Francesca Bonifazi, Pier Luigi Zinzani, Antonio Curti, Maria Rosa Motta, Simonetta Rizzi, Valeria Giudice, Oriana Farese, Manuela Rovito, Lapo Alinari, Roberto Conte, and Michele Baccarani

full text 55 kb

66

  

Pegfilgrastim Alone Successfully Mobilizes Peripheral CD34+ Cells in Chemotherapy-Naïve Subjects With Solid Tumors
Fenella Willis, Ruth Pettengell, Penella J. Woll, Claire Desborough, and Karen Buchanan

full text 59 kb

68

  

Pegylated Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplant
Madan H. Jagasia, John Greer, Adetola Kassim, Shin Mineishi, David Morgan, Katherine Ruffner, and Friedrich Schuening

full text 53 kb

70

  

Pegfilgrastim Shows Safety and Efficacy Similar to Filgrastim in Patients Undergoing Autologous Stem Cell Transplantation for Hematologic Malignancies
Peter Neumeister, Robert Holub, Phillipe B. Staber, and Werner Linkesch

full text 50 kb

Mucositis

73

  

Oral Mucositis Therapy Comes of Age
Patrick J. Stiff, MD, Guest Editor

Departments of Medicine and Pathology, Cardinal Bernardin Cancer Center, and Division of Hematology-Oncology, Loyola University Medical Center, Maywood, Illinois

full text 83 kb

76

  

Palifermin Reduces Estimated Downstream Costs of Autologous Stem Cell Transplant: Analysis of Phase III Trial Results
Linda S. Elting, Ya-Chen Tina Shih, Patrick J. Stiff, William Bensinger, Scott B. Cantor, Catherine Cooksley, and Ricardo Spielberger

full text 56 kb

78

  

Keratinocyte Growth Factor (Palifermin) in Combination With Tacrolimus and Methotrexate for the Prevention of Acute Graft- vs-Host-Disease (AGVHD) in Patients at High Risk of AGVHD
Christopher Reynolds, John Levine, Joseph Uberti, Voravit Ratanatharathorn, Lois Ayash, Samuel Silver, Gregory Yanik, Pavan Reddy, Kenneth Cooke, Michael Becker, Raymond Hutchinson, and James Ferrara

full text 52 kb

80

  

Phase I Trial of CG53135-05 to Prevent Mucositis in Patients Undergoing High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation
Michael W. Schuster, Tsiporah B. Shore, June Greenberg, Bita Jalilizeinali, Scott Possley, Vincent L. Annino, Thomas Hawthorne, Yuan-Di Halvorsen, and William Hahne

full text 52 kb

82

  

Pharmacokinetics and Pharmacodynamics of Palifermin in Healthy Volunteers After Intravenous Administration of Single Escalating Doses up to 250 µg/kg
Parnian Zia-Amirhosseini, Margaret Salfi, Philip Leese, and John T. Sullivan

full text 59 kb

Supported by an unrestricted educational grant from Amgen Inc.

© 2005 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.